PM
IOVA icon

Prosight Management’s Iovance Biotherapeutics IOVA Stock Holding History

Prosight Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$2.47M – 44
2021
Q3 		$2.47M Buy
+100,000
New +$2.36M 1.36% 27

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prosight Management's IOVA Position: Q2 2022 in Review

Prosight Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 20,000 shares — an estimated $333K sold.

Prosight Management first reported a position in IOVA in Q4 2017 and held it in 16 quarters. The position peaked at $16.6M in Q1 2020. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Prosight Management reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Prosight Management sold 20,000 Iovance Biotherapeutics shares in Q2 2022, an estimated $333K.
  • Prosight Management first reported a position in Iovance Biotherapeutics in Q4 2017 and held it in 16 quarters.
  • Prosight Management's Iovance Biotherapeutics position peaked at $16.6M in Q1 2020.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.